Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Chaperon Protein GRP78 Released from MPN Cells Increase Expression of Lysyl Oxidase in Human Stroma Cell Line

Kei Nakajima, Keita Kirito

Blood (2023) 142 (Supplement 1): 3157.

https://doi.org/10.1182/blood-2023-180709

Published: 2023

Journal Articles

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Blood (2023) 142 (Supplement 1): 620.

https://doi.org/10.1182/blood-2023-173509

Published: 2023

Journal Articles

Thrombotic and Bleeding Events in Japanese Adolescent and Young Adult PV and ET: Results from Japanese Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 1831.

https://doi.org/10.1182/blood-2023-180561

Published: 2023

Journal Articles

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Blood (2022) 140 (Supplement 1): 12162–12164.

https://doi.org/10.1182/blood-2022-162516

Published: 2022

Journal Articles

The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply

Keita Kirito, MD, Kazuya Shimoda, MD PhD, Katsuto Takenaka, MD PhD, Albert Qin, MD PhD, Oleh Zagrijtschuk, MD, Toshiaki Sato, MD PhD, Narihisa Miyachi, Hiroaki Kawase, Katsuya Yonezu, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142504

Published: 2020

Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Blood (2018) 132 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2018-99-115129

Published: 2018

Journal Articles

Metformin Suppresses Expression of Pre-Fibrotic Enzyme Lysyl-Oxidase Levels through Inhibition of UPR in MPN Cells

Megumi Suzuki, MD, Ichiro Kawashima, Keita Kirito, MD

Blood (2018) 132 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2018-99-113276

Published: 2018

Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Blood (2017) 130 (Supplement 1): 322.

https://doi.org/10.1182/blood.V130.Suppl_1.322.322

Published: 2017

Journal Articles

Aberrant Activation of NF-κB and Hypoxia Enhances Glycolytic Enzyme Hexokinase II Expression in B-Cell Lymphoma through Activation of HIF-1

Kei Nakajima, Keita Kirito, MD, Ichiro Kawashima, Megumi Koshiishi, Takuma Kumagai, Toru Mitsumori

Blood (2017) 130 (Supplement 1): 4025.

https://doi.org/10.1182/blood.V130.Suppl_1.4025.4025

Published: 2017

Journal Articles

Assessing the Safety and Efficacy of Ruxolitinib in a Multicenter, Open-Label, Expanded-Access Study in Japanese Patients with Myelofibrosis (MF)

Keita Kirito, MD, Norio Komatsu, MD PhD, Kazuya Shimoda, MD PhD, Hikaru Okada, MD PhD, Taro Amagasaki, PhD, Toshio Yonezu, MSc, Koichi Akashi, MD PhD

Blood (2015) 126 (23): 1625.

https://doi.org/10.1182/blood.V126.23.1625.1625

Published: 2015

Journal Articles

Metformin Inhibits JAK2V617F Activity By Activating AMPK and PP2A Containing B56 Alpha Subunits in MPN Cells

Ichiro Kawashima, MD, Keita Kirito, MD

Blood (2015) 126 (23): 1636.

https://doi.org/10.1182/blood.V126.23.1636.1636

Published: 2015

Journal Articles

Metformin Exerts Anti-Leukemic Effects Via Direct Inhibition Of Oncogenic Kinase Activity In Leukemia Cells Derived From Myeloproliferative Neoplasms

Ichiro Kawashima, MD, Keita Kirito, MD, PhD

Blood (2013) 122 (21): 2853.

https://doi.org/10.1182/blood.V122.21.2853.2853

Published: 2013

Journal Articles

The Genetic Landscape Of FPD/AML Revealed CDC25C Mutation As a Driver That Promotes Malignant Transformation

Akihide Yoshimi, MD, PhD, Takashi Toya, MD, Masahiro Nakagawa, MD, PhD, Masahito Kawazu, MD, PhD, Yasuhito Nannya, MD, PhD, Motoshi Ichikawa, MD, PhD, Shunya Arai, MD, PhD, Hironori Harada, MD, PhD, Kensuke Usuki, MD, PhD, Yasuhide Hayashi, MD, PhD, Etsuro Ito, MD, PhD, Keita Kirito, MD, PhD, Hideaki Nakajima, MD, PhD, Hiroyuki Mano, MD, PhD, Mineo Kurokawa, MD, PhD

Blood (2013) 122 (21): 739.

https://doi.org/10.1182/blood.V122.21.739.739

Published: 2013

Journal Articles

Hypoxia Blocks Activation of JAK2V617F Through Suppression of SHP-2 Expression in MPN Cells

Toru Mitsumori, MD, Yumi Nozaki, MD, Norio Komatsu, M.D., Ph.D., Keita Kirito, MD

Blood (2011) 118 (21): 126.

https://doi.org/10.1182/blood.V118.21.126.126

Published: 2011

Journal Articles

Rituximab Activation of AKT and HIF Pathways Is Dependent on Membrane Lipid Raft Cholesterol Levels in Lymphoma Cells

Yumi Nozaki, MD, Toru Mitsumori, MD, Norio Komatsu, M.D., Ph.D., Keita Kirito, MD

Blood (2011) 118 (21): 1571.

https://doi.org/10.1182/blood.V118.21.1571.1571

Published: 2011

Journal Articles

Alternately Binding Quenching Probe Competitive PCR: Simple, Sensitive, and Cost-Effective JAK2 Allele Burden Quantification Method

Soji Morishita, Naohiro Noda, Ph.D, Yuji Sekiguchi, Ph.D, Aya H Koda, Ph.D, Yuriko Yahata, MD, Keita Kirito, MD, Satoshi Tsuneda, Ph.D, Norio Komatsu

Blood (2010) 116 (21): 1972.

https://doi.org/10.1182/blood.V116.21.1972.1972

Published: 2010

Journal Articles

Evaluation of Romiplostim In a Randomized Placebo-Controlled Phase 3 Study of a Japanese Population with Chronic Immune Thrombocytopenia (ITP).

Koji Miyazaki, MD, Yukari Shirasugi, MD, Kiyoshi Ando, MD, PhD, Yoshiaki Tomiyama, MD, Shinichiro Okamoto, MD, PhD, Mineo Kurokawa, MD, Keita Kirito, MD, Yuji Yonemura, MD, PhD, Shinichiro Mori, MD, Kensuke Usuki, MD, PhD, Koji Iwato, MD, PhD, Satoshi Hashino, MD, PhD, Helen Wei, PhD, Richard Lizambri, MD

Blood (2010) 116 (21): 3704.

https://doi.org/10.1182/blood.V116.21.3704.3704

Published: 2010

Journal Articles

Impact of Protein Phosphatase PP2A on ATRA-Induced Activation of FoxO3a In Acute Promyelocytic Leukemia Cells

Yasuhiko Sakoe, Kumi Sakoe, Haruo Shimazaki, Keita Kirito, MD, Norio Komatsu

Blood (2010) 116 (21): 2492.

https://doi.org/10.1182/blood.V116.21.2492.2492

Published: 2010

Journal Articles

FOXO3A as a key molecule for all- trans retinoic acid–induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia

Yasuhiko Sakoe, Kumi Sakoe, Keita Kirito, Keiya Ozawa, Norio Komatsu

Blood (2010) 115 (18): 3787–3795.

https://doi.org/10.1182/blood-2009-05-222976

Published: 2010

Includes: Supplemental data

Journal Articles

HIF-1 Prevents Hematopoietic Cells from Cell Damage by Overproduction of Mitochondrial ROS after Cytokine Stimulation through Induction of PDK-1

Keita Kirito, MD, Kozue Yoshida, Yongzhen Hu, Qiao Qiao, Kumi Sakoe, Norio Komatsu

Blood (2008) 112 (11): 2435.

https://doi.org/10.1182/blood.V112.11.2435.2435

Published: 2008

NARROW

Chaperon Protein GRP78 Released from MPN Cells Increase Expression of Lysyl Oxidase in Human Stroma Cell Line

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Thrombotic and Bleeding Events in Japanese Adolescent and Young Adult PV and ET: Results from Japanese Multicenter Retrospective Study

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Metformin Suppresses Expression of Pre-Fibrotic Enzyme Lysyl-Oxidase Levels through Inhibition of UPR in MPN Cells

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Aberrant Activation of NF-κB and Hypoxia Enhances Glycolytic Enzyme Hexokinase II Expression in B-Cell Lymphoma through Activation of HIF-1

Assessing the Safety and Efficacy of Ruxolitinib in a Multicenter, Open-Label, Expanded-Access Study in Japanese Patients with Myelofibrosis (MF)

Metformin Inhibits JAK2V617F Activity By Activating AMPK and PP2A Containing B56 Alpha Subunits in MPN Cells

Metformin Exerts Anti-Leukemic Effects Via Direct Inhibition Of Oncogenic Kinase Activity In Leukemia Cells Derived From Myeloproliferative Neoplasms

The Genetic Landscape Of FPD/AML Revealed CDC25C Mutation As a Driver That Promotes Malignant Transformation

Hypoxia Blocks Activation of JAK2V617F Through Suppression of SHP-2 Expression in MPN Cells

Rituximab Activation of AKT and HIF Pathways Is Dependent on Membrane Lipid Raft Cholesterol Levels in Lymphoma Cells

Alternately Binding Quenching Probe Competitive PCR: Simple, Sensitive, and Cost-Effective JAK2 Allele Burden Quantification Method

Evaluation of Romiplostim In a Randomized Placebo-Controlled Phase 3 Study of a Japanese Population with Chronic Immune Thrombocytopenia (ITP).

Impact of Protein Phosphatase PP2A on ATRA-Induced Activation of FoxO3a In Acute Promyelocytic Leukemia Cells

FOXO3A as a key molecule for all- trans retinoic acid–induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia

HIF-1 Prevents Hematopoietic Cells from Cell Damage by Overproduction of Mitochondrial ROS after Cytokine Stimulation through Induction of PDK-1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only